Retro Biosciences, founded in 2021 in Redwood City, California, develops therapies that target cellular drivers of ageing, including autophagy and cell replacement programmes. It launched with $180 million from Sam Altman and announced the initial close of a new round at a $1.8 billion pre-money valuation in May 2026.
At a glance
| Price from | Custom |
| Best for | Partners following ageing biology into the clinic |
From Retro Biosciences's own website.
What stands out
- Lead programme already in the clinic
- Strong investor backing
Worth knowing
- Latest round size not disclosed
- Early clinical stage
How it ranks
Retro Biosciences is ranked 3rd of 10 in Best Longevity Startups (Lister Score 94.3).
#3 in Best Longevity Startups · Lister Score 94.3
Retro says its lead candidate RTR242 entered the clinic in 2025..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Retro Biosciences rank on Lister?
Retro Biosciences is ranked 3rd of 10 in Best Longevity Startups (Lister Score 94.3).
Appears in
Add this badge to your site
If you work at Retro Biosciences, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.